Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani & Fatemeh Rahbarizadeh. (2022) Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Critical Reviews in Biotechnology 42:7, pages 1079-1098.
Read now
Read now
Chiara Ferraris, Roberta Cavalli, Pier Paolo Panciani & Luigi Battaglia. (2020) Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours. International Journal of Nanomedicine 15, pages 2999-3022.
Read now
Read now
Erika Rijavec, Carlo Genova, Giulia Barletta, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Irene Vanni, Angela Alama, Francesco Boccardo & Francesco Grossi. (2014) Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 15:12, pages 1771-1780.
Read now
Read now
Andreas Desiniotis & Natasha Kyprianou. (2011) Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opinion on Therapeutic Targets 15:12, pages 1405-1418.
Read now
Read now
N.H. Rekers, P. Sminia & G.J. Peters. (2011) Towards Tailored Therapy of Glioblastoma Multiforme. Journal of Chemotherapy 23:4, pages 187-199.
Read now
Read now
Rafael Roesler, André T Brunetto, Ana Lucia Abujamra, Caroline Brunetto de Farias, Algemir Lunardi Brunetto & Gilberto Schwartsmann. (2010) Current and emerging molecular targets in glioma. Expert Review of Anticancer Therapy 10:11, pages 1735-1751.
Read now
Read now
Articles from other publishers (40)
Gbolahan Olatunji, Nicholas Aderinto, Temiloluwa Adefusi, Emmanuel Kokori, Olumide Akinmoju, Ismaila Yusuf, Tobi Olusakin & Muhammad Ali Muzammil. (2023) Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence. Medicine 102:48, pages e36421.
Crossref
Crossref
Ashley B. Zhang, Khashayar Mozaffari, Brian Aguirre, Victor Li, Rohan Kubba, Nilay C. Desai, Darren Wei, Isaac Yang & Madhuri Wadehra. (2023) Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma. Cancers 15:3, pages 830.
Crossref
Crossref
Ram Prakash Thirugnanasambandam, Gaudy Massiel Vanegas Silva, Alexander H. Wu, Charles J. Kim, Emanuela Cimpeanu, Jeremy Minkowitz, Charles Yanping Shao & Edwin Chiu. (2023) Cystic Glioblastoma: A Mimicker of Infection? A Case Report and Literature Review. Case Reports in Oncological Medicine 2023, pages 1-8.
Crossref
Crossref
Laura Lorenzo‐Soler, Pitsiree Praphanwittaya, Olof Birna Olafsdottir, Iris Myrdal Kristinsdottir, Gudrun Marta Asgrimsdottir, Thorsteinn Loftsson & Einar Stefansson. (2022) Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye. Acta Ophthalmologica 100:7, pages 788-796.
Crossref
Crossref
Nishant S. Kulkarni & Vivek Gupta. (2022) Repurposing therapeutics for malignant pleural mesothelioma (MPM) – Updates on clinical translations and future outlook. Life Sciences 304, pages 120716.
Crossref
Crossref
Iyman Amin & Prashant Saxena. (2022) Glioblastoma a Malignant Form of Tumor: a Review on Its Cellular Target, Route, and Its Treatment. Current Tissue Microenvironment Reports 3:3, pages 51-60.
Crossref
Crossref
Shan Liu, An-Jing Wang, Min Li, Jing Zhang, Guo-Dong Yin, Wen-Ming Shu & Wei-Chu Yu. (2022) Rh(III)-Catalyzed Tandem Reaction Access to (Quinazolin-2-yl)methanone Derivatives from 2,1-Benzisoxazoles and α-Azido Ketones. The Journal of Organic Chemistry 87:16, pages 11253-11260.
Crossref
Crossref
Majid Momeny, Sahar Shamsaiegahkani, Bahareh Kashani, Sepideh Hamzehlou, Fatemeh Esmaeili, Hassan Yousefi, Shiva Irani, Seyed A. Mousavi & Seyed H. Ghaffari. (2021) Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells. Life Sciences 287, pages 120100.
Crossref
Crossref
Ani-Simona Sevastre, Alexandra Costachi, Ligia Tataranu, Corina Brandusa, Stefan Artene, Olivian Stovicek, Oana Alexandru, Suzana Danoiu, Veronica Sfredel & Anica Dricu. (2021) Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review). Experimental and Therapeutic Medicine 22:6.
Crossref
Crossref
Pritam Kumar Roy, Yetirajam Rajesh & Mahitosh Mandal. (2021) Therapeutic targeting of membrane-associated proteins in central nervous system tumors. Experimental Cell Research 406:2, pages 112760.
Crossref
Crossref
Sakthi Lenin, Elise Ponthier, Kaitlin G. Scheer, Erica C. F. Yeo, Melinda N. Tea, Lisa M. Ebert, Mariana Oksdath Mansilla, Santosh Poonnoose, Ulrich Baumgartner, Bryan W. Day, Rebecca J. Ormsby, Stuart M. Pitson & Guillermo A. Gomez. (2021) A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. International Journal of Molecular Sciences 22:9, pages 4322.
Crossref
Crossref
Shervin Taslimi, Vincent Ye, Patrick Y Wen & Gelareh Zadeh. (2021) Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: Part 2 Recurrent glioblastoma. Neuro-Oncology Advances.
Crossref
Crossref
Majid Momeny, Ghazaleh Sankanian, Sepideh Hamzehlou, Hassan Yousefi, Fatemeh Esmaeili, Zivar Alishahi, Behnaz Karimi, Zahra Zandi, Sahar Shamsaiegahkani, Zahra Sabourinejad, Bahareh Kashani, Ali Nasrollahzadeh, Seyyedeh H. Mousavipak, Seyed A. Mousavi & Seyed H. Ghaffari. (2020) Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells. European Journal of Pharmacology 882, pages 173298.
Crossref
Crossref
Kunal S Patel, Sameer Kejriwal, Samasuk Thammachantha, Courtney Duong, Adrian Murillo, Lynn K Gordon, Timothy F Cloughesy, Linda Liau, William Yong, Isaac Yang & Madhuri Wadehra. (2020) Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab. Neuro-Oncology Advances 2:1.
Crossref
Crossref
Bhaskar Venkata Kameswara Subrahmanya Lakkakula, Batoul Farran, Saikrishna Lakkakula, Sujatha Peela, Nagendra Sastry Yarla, Pallaval Veera Bramhachari, Mohammad Amjad Kamal, Madhu Sudhana Saddala & Ganji Purnachandra Nagaraju. (2019) Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles. Seminars in Cancer Biology 56, pages 149-167.
Crossref
Crossref
Weifeng Tang, Alex McCormick, Jianguo Li & Eric Masson. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. Clinical Pharmacokinetics 56:7, pages 689-702.
Crossref
Crossref
Dong Woo Lee, Sang-Yun Lee, Il Doh, Gyu Ha Ryu & Do-Hyun Nam. (2017) High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform. BioMed Research International 2017, pages 1-7.
Crossref
Crossref
Thomas J. Hayman & Joseph N. Contessa. 2017. Increasing the Therapeutic Ratio of Radiotherapy. Increasing the Therapeutic Ratio of Radiotherapy
35
55
.
Giovanna Mirone, Stefania Perna & Gabriella Marfe. 2016. Resistance to Tyrosine Kinase Inhibitors. Resistance to Tyrosine Kinase Inhibitors
27
107
.
Yanyan Jiang, Danny Allen, Veerle Kersemans, Aoife M. Devery, Sivan M. Bokobza, Sean Smart & Anderson J. Ryan. (2015) Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Lung Cancer 90:2, pages 191-198.
Crossref
Crossref
Tanveer A. Wani & Ibrahim A. Darwish. (2015) Development and validation of ultra-performance liquid chromatography-tandem mass spectrometry method for determination of cediranib in human plasma. Main Group Chemistry 14:4, pages 349-357.
Crossref
Crossref
Anna Shivinsky, Tomer Bronshtein, Tom Haber & Marcelle Machluf. (2015) The effect of AZD2171- or sTRAIL/Apo2L-loaded polylactic-co-glycolic acid microspheres on a subcutaneous glioblastoma model. Biomedical Microdevices 17:4.
Crossref
Crossref
Sara G.M. Piccirillo, Inmaculada Spiteri, Andrea Sottoriva, Anestis Touloumis, Suzan Ber, Stephen J. Price, Richard Heywood, Nicola-Jane Francis, Karen D. Howarth, Vincent P. Collins, Ashok R. Venkitaraman, Christina Curtis, John C. Marioni, Simon Tavaré & Colin Watts. (2015) Contributions to Drug Resistance in Glioblastoma Derived from Malignant Cells in the Sub-Ependymal Zone. Cancer Research 75:1, pages 194-202.
Crossref
Crossref
Maxim A. Shevtsov, Boris P. Nikolaev, Ludmila Y. Yakovleva, Anatolii V. Dobrodumov, Alexander V. Zhakhov, Anastasiy L. Mikhrina, Emil Pitkin, Marina A. Parr, Valerii I. Rolich, Andrei S. Simbircev & Alexander M. Ischenko. (2015) Recombinant Interleukin-1 Receptor Antagonist Conjugated to Superparamagnetic Iron Oxide Nanoparticles for Theranostic Targeting of Experimental Glioblastoma. Neoplasia 17:1, pages 32-42.
Crossref
Crossref
Yi Hu, Huiru Lu, Jinchao Zhang, Jun Chen, Zhifang Chai & Jingxin Zhang. (2014) Essential role of AKT in tumor cells addicted to FGFR. Anti-Cancer Drugs 25:2, pages 183-188.
Crossref
Crossref
Han Kiat Ho, Angie Hui Ling Yeo, Tse Siang Kang & Boon Tin Chua. (2014) Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discovery Today 19:1, pages 51-62.
Crossref
Crossref
Anna Burford, Suzanne E. Little, Alexa Jury, Sergey Popov, Ross Laxton, Lawrence Doey, Safa Al-Sarraj, Juliane M. Jürgensmeier & Chris Jones. (2013) Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma. PLoS ONE 8:8, pages e71777.
Crossref
Crossref
William L. Dahut, Ravi A. Madan, Joyson J. Karakunnel, David Adelberg, James L. Gulley, Ismail B. Turkbey, Cindy H. Chau, Shawn D. Spencer, Marcia Mulquin, John Wright, Howard L. Parnes, Seth M. Steinberg, Peter L. Choyke & William D. Figg. (2013)
Phase
II
clinical trial of cediranib in patients with metastatic castration‐resistant prostate cancer
. BJU International 111:8, pages 1269-1280.
Crossref
Crossref
Louisa Bokacheva, Khushali Kotedia, Megan Reese, Sally-Ann Ricketts, Jane Halliday, Carl H. Le, Jason A. Koutcher & Sean Carlin. (2013)
Response of HT29 colorectal xenograft model to cediranib assessed with
18
F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI
. NMR in Biomedicine 26:2, pages 151-163.
Crossref
Crossref
Flavia R.S. Lima, Suzana Assad Kahn, Rossana C. Soletti, Deborah Biasoli, Tercia Alves, Anna Carolina C. da Fonseca, Celina Garcia, Luciana Romão, José Brito, Rosenilde Holanda-Afonso, Jane Faria, Helena Borges & Vivaldo Moura-Neto. (2012) Glioblastoma: Therapeutic challenges, what lies ahead. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1826:2, pages 338-349.
Crossref
Crossref
Jake S. Burrell, Simon Walker-Samuel, Lauren C.J. Baker, Jessica K.R. Boult, Yann Jamin, Anderson J. Ryan, John C. Waterton, Jane Halliday & Simon P. Robinson. (2012) Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. International Journal of Cancer 131:8, pages 1854-1862.
Crossref
Crossref
Saroj Kunnakkat, Maya Mathew & Ashwatha Narayana. (2012) Antiangiogenic therapy in the management of brain tumors: a clinical overview. Cancer Chemotherapy and Pharmacology 70:3, pages 353-363.
Crossref
Crossref
Sabine TejparHans PrenenMassimiliano Mazzone. (2012) Overcoming Resistance to Antiangiogenic Therapies. The Oncologist 17:8, pages 1039-1050.
Crossref
Crossref
Tianli Wang, Rajneet K. Oberoi & William F. Elmquist. (2011) Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography–mass spectrometry. Journal of Chromatography B 879:32, pages 3812-3817.
Crossref
Crossref
Yan Michael Li & Walter A Hall. (2011) Cell Surface Receptors in Malignant Glioma. Neurosurgery 69:4, pages 980-994.
Crossref
Crossref
Domenico Ribatti. (2011) Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Reviews 37:5, pages 344-352.
Crossref
Crossref
Leopold Arko, Igor Katsyv, Grace E. Park, William Patrick Luan & John K. Park. (2010) Experimental approaches for the treatment of malignant gliomas. Pharmacology & Therapeutics 128:1, pages 1-36.
Crossref
Crossref
Donald J. AbrahamRobertson Graeme. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
223
294
.
Lucia Magnelli, Riccardo Caldini, Nicola Schiavone, Hisanori Suzuki & Marta Chevanne. (2010) Differentiating and Apoptotic Dose-Dependent Effects in (−)-α-Bisabolol-Treated Human Endothelial Cells. Journal of Natural Products 73:4, pages 523-526.
Crossref
Crossref
Emily S. Robinson, Ursula A. Matulonis, Percy Ivy, Suzanne T. Berlin, Karin Tyburski, Richard T. Penson & Benjamin D. Humphreys. (2010) Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor. Clinical Journal of the American Society of Nephrology 5:3, pages 477-483.
Crossref
Crossref